Literature DB >> 19400867

Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.

Jes Dietrich1, T Mark Doherty.   

Abstract

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), remains a major worldwide health problem that causes more than 2 million deaths annually. In addition, an estimated 2 billion people are latently infected with M. tuberculosis. The bacterium is one of the oldest human pathogens and has evolved complex strategies for survival. Therefore, to be successful in the high endemic regions, any future TB vaccine strategy will have to be tailored in accordance with the resulting complexity of the TB infection and anti-mycobacterial immune response. In this review, we will discuss what is presently known about the interaction of M. tuberculosis with the immune system, and how this knowledge is used in new and more advanced vaccine strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19400867     DOI: 10.1111/j.1600-0463.2009.02458.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  23 in total

1.  Commonly administered bacille Calmette-Guerin strains induce comparable immune response.

Authors:  Jun-Fang Wang; Fu-Ying Dai; Xue-Li Gong; Lang Bao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Mycobacterial induction of autophagy varies by species and occurs independently of mammalian target of rapamycin inhibition.

Authors:  Alfred J Zullo; Sunhee Lee
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

Review 3.  Clinical immunology and multiplex biomarkers of human tuberculosis.

Authors:  Gerhard Walzl; Mariëlle C Haks; Simone A Joosten; Léanie Kleynhans; Katharina Ronacher; Tom H M Ottenhoff
Journal:  Cold Spring Harb Perspect Med       Date:  2014-12-04       Impact factor: 6.915

4.  Signal peptides and trans-membrane regions are broadly immunogenic and have high CD8+ T cell epitope densities: Implications for vaccine development.

Authors:  Riva Kovjazin; Ilan Volovitz; Yair Daon; Tal Vider-Shalit; Roy Azran; Lea Tsaban; Lior Carmon; Yoram Louzoun
Journal:  Mol Immunol       Date:  2011-02-12       Impact factor: 4.407

Review 5.  Tuberculosis: what we don't know can, and does, hurt us.

Authors:  David G Russell; Clifton E Barry; JoAnne L Flynn
Journal:  Science       Date:  2010-05-14       Impact factor: 47.728

6.  Assessment of Hematological Parameters in Pulmonary Tuberculosis Patients.

Authors:  K Rohini; M Surekha Bhat; P S Srikumar; A Mahesh Kumar
Journal:  Indian J Clin Biochem       Date:  2015-11-17

Review 7.  The immunology of tuberculosis: from bench to bedside.

Authors:  Keertan Dheda; Stephan K Schwander; Bingdong Zhu; Richard N van Zyl-Smit; Ying Zhang
Journal:  Respirology       Date:  2010-04       Impact factor: 6.424

8.  Computational prediction and experimental assessment of secreted/surface proteins from Mycobacterium tuberculosis H37Rv.

Authors:  Carolina Vizcaíno; Daniel Restrepo-Montoya; Diana Rodríguez; Luis F Niño; Marisol Ocampo; Magnolia Vanegas; María T Reguero; Nora L Martínez; Manuel E Patarroyo; Manuel A Patarroyo
Journal:  PLoS Comput Biol       Date:  2010-06-24       Impact factor: 4.475

9.  Characterization of novel multiantigenic vaccine candidates with pan-HLA coverage against Mycobacterium tuberculosis.

Authors:  Riva Kovjazin; David Shitrit; Rachel Preiss; Ilanit Haim; Lev Triezer; Leonardo Fuks; Abdel Rahman Nader; Meir Raz; Ritta Bardenstein; Galit Horn; Nechama I Smorodinsky; Lior Carmon
Journal:  Clin Vaccine Immunol       Date:  2013-01-02

Review 10.  Macrophages in tuberculosis: friend or foe.

Authors:  Evelyn Guirado; Larry S Schlesinger; Gilla Kaplan
Journal:  Semin Immunopathol       Date:  2013-07-18       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.